Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Renovacor, Inc.CHAQ · Entity 114644 | Director | April 23, 2020 | April 27, 2020 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | 10% owner | July 12, 2023 | July 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Renovacor, Inc.
Report date April 23, 2020 · Filed April 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2020-04-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 |
Taysha Gene Therapies, Inc.
Report date July 12, 2023 · Filed July 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,871,747 |
Ending reported balance
After 2023-07-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-12 · Sale · Disposed 80,528 · Balance 8,877,091 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2023-07-13 · Sale · Disposed 5,344 · Balance 8,871,747 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 141,090 |
Reported balance
Holding disclosure · report date 2023-07-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 141,090 F2: The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 141,090 |
Reported balance
Holding disclosure · report date 2023-07-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 141,090 F3: The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
F3: The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Disposed 1,667 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 1,667 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.75 · Expires 2027-03-20 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 35,950 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.24 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 1,282 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 6,572 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 1,667 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2023 Filed Jul 14, 2023 20:00 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 5,344 | $0.70 | $3,740.80 |
DisclosureSEC source: 0000950170-23-032986 · ownership.xml · nonDerivative · entry 2 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,871,747 Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 20:00 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 80,528 | $0.71 | $57,029.93 |
DisclosureSEC source: 0000950170-23-032986 · ownership.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,877,091 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:46 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 18,100 | $0.70 | $12,735.16 |
DisclosureSEC source: 0000899243-23-016491 · doc4.xml · nonDerivative · entry 2 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,957,619 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.716. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:46 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 10,508 | $0.70 | $7,383.97 |
DisclosureSEC source: 0000899243-23-016491 · doc4.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,975,719 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.7185. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 20:00 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 138,962 | $0.70 | $97,634.70 |
DisclosureSEC source: 0000899243-23-016232 · doc4.xml · nonDerivative · entry 2 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,986,227 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.719. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:00 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 295,653 | $0.71 | $210,209.28 |
DisclosureSEC source: 0000899243-23-016232 · doc4.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,125,189 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.78. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 00:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 199,500 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001209191-23-017342 · doc4.xml · derivative · entry 4 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 199,500 shares Expires 2032-11-10 F7 · price: This option was canceled by mutual agreement of the Issuer and the Reporting Person. The Reporting Person received the RSU Award in exchange for the cancellation of this option. F6 · derivative.exercise_date: Prior to the cancellation of this option, 25% of the total number of shares underlying the option were to vest and become exercisable on November 10, 2023 and the remainder were to vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 00:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | OtherCommon Stock | 251,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017342 · doc4.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,420,842 F1 · kind: Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors (the "RSU Award"). The RSU Award replaced a prior stock option award of 199,500 shares of similar value that was canceled effective March 6, 2023. F2 · shares: Each share is represented by an RSU. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs are fully vested. F3 · balance_after: In connection with the Reporting Person's separation from the Issuer, the Reporting Person forfeited 21,374 unvested shares pursuant to a restricted stock award. Read SEC document |
| November 10, 2022 Filed Dec 23, 2022 21:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 199,500 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001209191-22-062615 · doc4.xml · derivative · entry 1 Session R.A. II · CIK 0001701846 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,500 Underlying: Common Stock · 199,500 shares Expires 2032-11-10 F1 · security: Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors on November 10, 2022. F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on November 10, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:17 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 217,850 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001209191-22-013156 · doc4.xml · derivative · entry 1 Session R.A. II · CIK 0001701846 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,850 Underlying: Common Stock · 217,850 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 23, 2021 Filed Dec 8, 2021 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 26,008 | $12.65 | $329,001.20 |
DisclosureSEC source: 0001209191-21-068510 · doc4.xml · nonDerivative · entry 2 Session R.A. II · CIK 0001701846 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,190,920 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.46 to $12.94 inclusive. Read SEC document |
| November 23, 2021 Filed Dec 8, 2021 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 16,510 | $12.12 | $200,101.20 |
DisclosureSEC source: 0001209191-21-068510 · doc4.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,164,912 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.46 to $12.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2). Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:22 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (Right to Buy) · Derivative | 199,700 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004573 · doc4.xml · derivative · entry 1 Session R.A. II · CIK 0001701846 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,700 Underlying: Common Stock · 199,700 shares Expires 2031-01-19 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:39 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,572 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-030129 · doc4.xml · derivative · entry 4 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,572 shares Expires 2028-03-13 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:39 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,282 | $0.00 Strike: $77.24 | $0.00 |
DisclosureSEC source: 0001209191-18-030129 · doc4.xml · derivative · entry 3 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,282 shares Expires 2027-05-10 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:39 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,950 | $0.00 Strike: $79.75 | $0.00 |
DisclosureSEC source: 0001209191-18-030129 · doc4.xml · derivative · entry 2 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,950 shares Expires 2027-03-20 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:39 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030129 · doc4.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2 · shares: Represents 1,667 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Read SEC document |
| March 13, 2018 Filed Mar 27, 2018 17:34 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,572 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-021795 · doc4.xml · derivative · entry 2 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,572 Underlying: Common Stock · 6,572 shares Expires 2028-03-13 F2 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on March 13, 2019; the remaining shares shall vest in 36 equal monthly installments beginning on April 13, 2019, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| March 13, 2018 Filed Mar 27, 2018 17:34 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021795 · doc4.xml · nonDerivative · entry 1 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date. F1 · price: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| May 10, 2017 Filed May 12, 2017 18:34 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,282 | $0.00 Strike: $77.24 | $0.00 |
DisclosureSEC source: 0001209191-17-032156 · doc4.xml · derivative · entry 1 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282 Underlying: Common Stock · 1,282 shares Expires 2027-05-10 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on May 10, 2018; the remaining shares shall vest in 36 equal monthly installments beginning on June 10, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| March 20, 2017 Filed Mar 23, 2017 16:21 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,950 | $0.00 Strike: $79.75 | $0.00 |
DisclosureSEC source: 0001209191-17-022565 · doc4.xml · derivative · entry 1 Session R.A. II · CIK 0001701846 · Sr. VP, Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,950 Underlying: Common Stock · 35,950 shares Expires 2027-03-20 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable as to 8,987 shares on March 20, 2018; and the remainder shall vest and become exercisable in 36 equal installments on the last day of each calendar month, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Plan) through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.